Neurim Pharmaceuticals Expands Slenyto® Approval for ADHD
Neurim Pharmaceuticals announces that the European Commission has granted an important extension for Slenyto®, a prolonged-release melatonin formulation indicated for the treatment of insomnia. This approval specifically addresses the needs of children diagnosed with attention deficit hyperactivity disorder (ADHD). With this significant development, Neurim is poised to offer a vital solution to families struggling with sleep issues related to ADHD.
Understanding Slenyto®
Slenyto® was initially approved within the European Union for children with autism spectrum disorder (ASD) in 2018, providing a unique pharmacological treatment option for insomnia. Following its initial success, the indication was further expanded to include children with neurogenetic disorders in 2024. Slenyto® stands out as the only authorized medication to specifically help with insomnia linked to these conditions.
Newly Extended Indication
The latest approval by the European Commission allows for the treatment of insomnia in children with ADHD aged 6 to 17 years, emphasizing the importance of addressing sleep issues as part of a comprehensive treatment approach. This development will not only help with sleep initiation but also enhance sleep maintenance and overall sleep duration. Prof. Nava Zisapel, CEO of Neurim Pharmaceuticals, highlighted the unmet needs in this area, and the extended indication for Slenyto® represents a critical step in addressing these challenges.
Expert Opinions on Slenyto®
Prominent experts such as Prof. Carmen Schroder and Prof. Oliviero Bruni have praised Slenyto®, pointing out its ability to mimic the body's natural release of melatonin, which can foster improved sleep quality for children with ADHD. They noted that many children face significant sleep disturbances, which can greatly impact their overall well-being and behavior. Slenyto® aims to tackle these issues effectively, thereby improving both child and parent quality of life.
Challenges of ADHD and Sleep Disorders
Sleep problems are prevalent among children with ADHD, affecting up to 70% of this population. Such sleep disruptions can begin at an early age, often surfacing before a formal ADHD diagnosis. Research shows that inadequate sleep in these children can worsen ADHD symptoms and negatively impact daily functioning for both the children and their caregivers. Thus, enhancing sleep hygiene is a critical component of management strategies for ADHD.
Behavioral Interventions and Pharmacological Solutions
Organizations currently recommend behavioral sleep interventions as a primary approach for managing insomnia among pediatric ADHD cases. However, Slenyto® presents a novel pharmacological option for families who seek an additional tool in addressing these sleep issues, enhancing both initiation and maintenance of sleep.
Exploring the Composition and Efficacy of Slenyto®
Slenyto® features a tailored formulation of melatonin specifically crafted for children, making it easier to swallow and ensuring that it meets the unique needs of children suffering from insomnia. This innovative design allows Slenyto® to effectively deliver melatonin across the night, replicating the melatonin release profile typical in healthy children. Clinical studies on Slenyto® have demonstrated improvements in sleep onset, duration, and overall quality of sleep.
Impact on Behavioral Outcomes
Beyond sleep quality, positive effects of Slenyto® have been observed on externalizing behavior in children, emphasizing the importance of uninterrupted sleep. Enhanced sleep patterns have been linked to better behavioral outcomes, which in turn contribute to greater parent satisfaction and improved quality of life. The findings suggest that Slenyto® could significantly assist in the management of ADHD and its associated sleep disturbances.
About Neurim Pharmaceuticals
Neurim Pharmaceuticals Ltd. is a pioneering company focused on drug discovery and development centered on neuroscience. With its flagship product, CIRCADIN®, already helping patients over 55 with insomnia, Neurim continues to advance its product pipeline that targets central nervous system disorders. The successful expansion of Slenyto® underscores Neurim's commitment to innovative solutions in pediatric sleep health.
For more information regarding Neurim Pharmaceuticals and its offerings, visit their official site.
Frequently Asked Questions
What is Slenyto® and its purpose?
Slenyto® is a prolonged-release melatonin formulation used to treat insomnia in children with ADHD and other neurodevelopmental disorders.
What age group is approved for Slenyto® use in treating ADHD?
Slenyto® is approved for children and adolescents aged 6 to 17 years with ADHD who face sleep difficulties.
How does Slenyto® differ from other sleep aids?
Slenyto® specifically mimics the body's natural melatonin release pattern, making it suitable for children with neurodevelopmental disorders.
What impact does Slenyto® have on overall health?
Beyond improving sleep quality, Slenyto® has been associated with better behavioral outcomes in children, enhancing both family well-being and parenting satisfaction.
What is Neurim Pharmaceuticals' focus?
Neurim Pharmaceuticals is focused on developing innovative treatments for sleep disorders and continues to expand its product pipeline aimed at CNS disorders.
